Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Rescuing vision by direct reprogramming of human fibroblasts into retinal progenitor cells with small molecules
Author Affiliations & Notes
  • Yueh-Chang Lee
    Department of Ophthalmology, Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
    Genomics Research Center Academia Sinica, Taipei, Taiwan
  • Yao-Tseng Wen
    Institute of Eye Research, Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
  • Rong-Kung Tsai
    Institute of Eye Research, Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
    Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan
  • Jean Lu
    Genomics Research Center Academia Sinica, Taipei, Taiwan
  • Footnotes
    Commercial Relationships   Yueh-Chang Lee None; Yao-Tseng Wen None; Rong-Kung Tsai None; Jean Lu None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 1537. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yueh-Chang Lee, Yao-Tseng Wen, Rong-Kung Tsai, Jean Lu; Rescuing vision by direct reprogramming of human fibroblasts into retinal progenitor cells with small molecules. Invest. Ophthalmol. Vis. Sci. 2024;65(7):1537.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In clinical trials, retinal progenitor cells (RPCs) are anticipated to rescue vision in late-stage photoreceptor degeneration, but the availability of primary human RPCs is limited to fetal tissue. We developed a method to directly reprogram human fibroblasts (HFs) into RPCs with small molecules, and tested its safety and therapeutic efficacy in a rodent model of photoreceptor loss.

Methods : HFs were transduced with Vsx2–eGFP reporter, to determine the conversion of induced retinal progenitor cells (iRPCs). By fluorescence activated cell sorting (FACS), we sorted Vsx2–eGFP+ cells, and checked the gene expression profile utilizing quantitative reverse transcription PCR (qRT-PCR), and bulk RNA sequencing. To test in vitro potency, we used fura-2-based imaging to study glutamate receptor-mediated [Ca2+] i changes in fibroblasts and iRPCs. To test in vivo safety and therapeutic efficacy, one eye of Royal College of Surgeons (RCS) rat at P21 were subretinally transplanted with 5 μL of 2*105 cell suspension containing PBS (N=4), HFs (N=4), or iRPCs (N=4). The rats were then analyzed with electroretinogram (ERG) and light aversion tests monthly. At 4 month age, the eyes were cryo-fixed and sectioned for immunohistochemistry.

Results : After chemical reprogramming, there were 42.8% Vsx2–eGFP+ cells on FACS. In qRT-PCR, statistically significant increase (>1000 folds) of Vsx2 expression was found in iRPCs. In bulk RNA sequencing, iRPCs demonstrated upregulated expression of transcripts related to the extracellular matrix component, axon, dendrite, synaptic and postsynaptic membrane, and transport vesicle formation (p<0.003). In fura-2-based imaging, intracellular calcium concentrations were found to elevate in iRPCs upon glutamate stimulation (1mM), whereas HFs showed no response. In RCS rats, there was an improvement of ERG in the eyes transplanted with iRPCs at P28 and P56 (p<0.05). In light aversion test at P112, RCS rats transplanted with iRPCs were found to spend significantly more time in the dark space, indicating vision rescue in late-stage photoreceptor loss. In immunohistochemistry, we found survival and integration of iRPCs in layer of rat photoreceptors, with layer-by-layer retinal morphology well preserved.

Conclusions : By chemical reprogramming of human fibroblasts into induced retinal progenitor cells, we demonstrated its therapeutic potential in photoreceptor degeneration.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×